2022
Treatment discontinuation, patient-reported toxicities and quality-of-life by age following trastuzumab emtansine or paclitaxel/trastuzumab (ATEMPT)
Sella T, Zheng Y, Tayob N, Ruddy K, Freedman R, Dang C, Yardley D, Isakoff S, Valero V, DeMeo M, Burstein H, Winer E, Wolff A, Krop I, Partridge A, Tolaney S. Treatment discontinuation, patient-reported toxicities and quality-of-life by age following trastuzumab emtansine or paclitaxel/trastuzumab (ATEMPT). Npj Breast Cancer 2022, 8: 127. PMID: 36450763, PMCID: PMC9712612, DOI: 10.1038/s41523-022-00495-x.Peer-Reviewed Original ResearchHER2-positive breast cancerPatient-reported toxicityPatient-reported outcomesT-DM1Treatment discontinuationTrastuzumab emtansineBreast cancerStage I HER2-positive breast cancerAdjuvant trastuzumab emtansineExcellent disease outcomesLess activity impairmentPaclitaxel/trastuzumabSocial/familyPositive breast cancerSuperior QoLOlder patientsTreatment toleranceTreatment armsTreatment regimensEligible participantsGlobal QoLTherapy optionsActivity impairmentMultivariable modelDisease outcome
2002
Complementary and alternative medicine use among women with breast cancer.
DiGianni LM, Garber JE, Winer EP. Complementary and alternative medicine use among women with breast cancer. Journal Of Clinical Oncology 2002, 20: 34s-8s. PMID: 12235222.Peer-Reviewed Original ResearchConceptsAlternative medicine useBreast cancer patientsCAM useBreast cancerCancer patientsMedicine useForm of CAMLittle scientific evidenceSocial support groupsTreatment regimensCancer preventionPsychosocial distressGeneral populationPsychosocial interventionsVariety of modalitiesDietary supplementsPatientsCancerSupport groupsWomenScientific evidenceBehavioral techniquesInterventionRegimensCAM